Study finds domperidone not associated with severe mental health outcomes in new mothers
Recent case reports and media stories have emerged suggesting that people using domperidone, a drug commonly prescribed off-label to stimulate breast milk production, may be at risk of developing worrisome psychiatric symptoms, particularly when abruptly discontinuing the drug. New research published today in Obstetrics & Gynecology has found no association between initiation of domperidone and an increased risk of new-onset psychosis or mental health diagnoses.
“Up until now, there have been little data on the link between domperidone and mental health concerns, beyond limited case reports and a recent Health Canada review of a small number of patients,” says lead author Dr. Jonathan Zipursky, General Internal Medicine physician and scientist at Sunnybrook Health Sciences Centre. “Given the number of people commonly prescribed the drug to help increase breast milk production, it’s important to explore its impact on a broader level.”
The retrospective study, led by researchers at Sunnybrook Research Institute and ICES, looked at postpartum individuals who gave birth between March 1, 2006, and March 1, 2022, in Ontario, Canada. Of the more than two million live births, 7,096 individuals filled prescriptions for domperidone within 56 days postpartum, according to the Ontario Drug benefits database. Using publicly available data, the researchers analyzed how many of these patients were diagnosed with postpartum psychosis or mental health hospitalization in the year following birth, comparing them to a matched cohort that did not take domperidone. The research team found no differences among the groups.
While approved in Canada for treating gastrointestinal disorders, domperidone is often prescribed for its off-target clinical effects which impact the pituitary gland and stimulate the release of prolactin, consequently promoting lactation. While studies have shown that mothers taking domperidone only have a modest increase in breast milk production, domperidone is commonly prescribed, with its prevalence of use increasing over the past two decades.
“Our study found that use of domperidone postpartum does not appear to be associated with serious mental health outcomes, says Dr. Zipursky, also a scientist at ICES. “It is reassuring that no large-scale mental health effects were observed. However, clinicians should remain cautious and monitor patients for adverse outcomes including psychiatric symptoms.”
Dr. Zipursky adds that the study should not be seen as a safety endorsement of the drug, which has been linked to heart complications.
“Patients and clinicians should continue to balance the potential adverse effects of domperidone with its relatively modest benefit of increasing breast milk supply.”
Sunnybrook Research Institute (SRI) is the research arm of Sunnybrook Health Sciences Centre, an internationally recognized academic health sciences centre fully affiliated with the University of Toronto. With well-established programs in basic and applied sciences which span across three scientific platforms and eleven clinical programs, SRI is developing innovations in care for the more than 1.1 million patient visits the hospital provides annually.
ICES is an independent, not-for-profit research and analytics institute that uses population-based health information to produce knowledge on a broad range of healthcare issues. ICES leads cutting-edge studies and analyses evaluating healthcare policy, delivery, and population outcomes. Our knowledge is highly regarded in Canada and abroad and is widely used by government, hospitals, planners, and practitioners to make decisions about healthcare delivery and to develop policy. For the latest ICES news, follow us on BlueSky and LinkedIn: @ICESOntario
FOR FURTHER INFORMATION PLEASE CONTACT:
Samantha Sexton
Manager, Research & Education Communications
Sunnybrook Health Sciences Centre
[email protected]
Charlotte Lam
Communications Associate
ICES
[email protected]
437-317-8804